Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02989116
Other study ID # 2015-A00383-46
Secondary ID 15-045
Status Recruiting
Phase N/A
First received May 27, 2016
Last updated December 7, 2016
Start date October 2015
Est. completion date December 2019

Study information

Verified date November 2016
Source University Hospital, Caen
Contact Bernard Guillois, Professor
Phone 02.31.25.27.64
Email guillois-b@chu-caen.fr
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a daily executive training to cognitive inhibition, working memory or mindfulness as compared to an active control condition has a near- and far-transfer impact on brain and behavioral measures as collected in children aged 9-10 years, either born preterm or full-term.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 2019
Est. primary completion date October 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 9 Years to 10 Years
Eligibility Inclusion Criteria for all children:

- Male or female

- Aged 9-10 years at inclusion

- French school curriculum (since 1st grade)

- Fully informed through the dedicated booklet

- Both parents gave their written consent

- Normal medical, neurological and brain imaging assessment

Inclusion criterion for non preterm children only:

- Full term pregnancy with no abnormal event (>= 37 weeks of amenorrhea)

Inclusion criterion for preterm children only:

- Delivery before 33 weeks of amenorrhea

Exclusion Criteria for all participants:

- Age over or under 9-10 years old at inclusion

- Monozygotic twins

- Restrictions to a Magnetic Resonance brain imaging exam: claustrophobia, metallic elements (cardiac implants, cochlear implants, metallic elements in the brain or the eyes and being close to the nervous system, metallic prothesis, braces), restless participants.

- Sudden cognitive impairments due to a stroke, head injury associated with loss of consciousness for more than one hour or encephalitis.

- Chronic neurological, psychiatric, infectious or liver condition, endocrine disruption.

- Past or current medical condition: cancer, diabetes, chronic lung condition, cardiac, metabolic, hematological, endocrine or immunological disorder.

- Medication assumed to interfere with brain imaging measures (psychotropics, hypnotics, anxiolytics, neuroleptics, benzodiazepine, steroidal anti-inflammatory, anti-epileptics, painkillers, muscle relaxants).

- Left-sided handedness

- Colour blindness or non-corrected visual disturbances

- Diagnosed developmental disorders

- Diagnosed cerebral palsy

- Diagnosed Fine motor disturbances

- Parents not affiliated to the Social Security

- Parents not able to join at each time of the study

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Behavioral:
Inhibition training
Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
Working memory training
Working memory training on a tactile tablet for a month (20 sessions of 15 min)
Mindfulness training
Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
Active control training
Active control training on a tactile tablet for a month (20 sessions of 15 min)
Genetic:
Saliva collection
Collection of a saliva sample for genotyping
Procedure:
Brain Magnetic Resonance Imaging
Structural and functional MRI
Behavioral:
Cognitive testing
Battery of cognitive and academic tasks on executive functions

Locations

Country Name City State
France GIP Cyceron Caen

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Caen National Research Agency, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in brain functional BOLD activity after one month of executive training as assessed by MRI in regions subtending executive functioning. Change in brain activation will be measured with functional magnetic resonance imaging (fMRI) during two different tasks: a Stop Signal task assessing inhibition and a Dot task assessing working memory. 3 months: Pretest (t0), immediate Post-test (t0+1 month), deferred post-test (t0+3 months) No
Primary Change in brain cortical structure after one month of executive training as assessed by anatomical MRI in regions subtending executive functioning. Change in brain cortical structure will be measured with anatomical magnetic resonance imaging (aMRI) using four different measures:
2.a. grey matter volume 2.b. cortical thickness 2.c. cortical surface area 2.d. curvature
3 months: Pretest (t0), immediate Post-test (t0+1 month), deferred post-test (t0+3 months) No
Primary Change in cognitive behavioral measures after one month of executive training as assessed by cognitive testing The cognitive testing session includes several tasks assessing executive functioning under different conditions. Will be investigated:
3.a. Response Time 3.b. Accuracy
3 months: Pretest (t0), immediate Post-test (t0+1 month), deferred post-test (t0+3 months) No
Secondary Sulcal morphometry measured by anatomical MRI Assessing the impact of the early determined sulcal morphometry on behavioral and brain changes associated to a one-month executive training. Pretest (t0) No
Secondary Genetic variations measured by Single Nucleotide Polymorphism (SNP) genotyping Assessing the impact of the different genotypes on behavioral and brain changes associated to a one-month executive training. Pretest (t0) No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Not yet recruiting NCT03418012 - Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB N/A
Not yet recruiting NCT03418311 - Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome N/A
Completed NCT02993744 - Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone N/A
Active, not recruiting NCT02673216 - Infection and Adverse Pregnancy Outcome
Completed NCT01683565 - Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Phase 4
Completed NCT01412931 - Protein and Ultrasound Indicators of Preterm Birth N/A
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Completed NCT02606058 - The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures? N/A
Terminated NCT03715530 - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women N/A
Completed NCT00422526 - Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial Phase 3
Enrolling by invitation NCT04251260 - Effectiveness of Positioning in Preterm Neonates N/A
Completed NCT03668860 - India Dexamethasone and Betamethasone Phase 1
Recruiting NCT03638037 - Correlation Between Maternal Vitamin D Level And Preterm Birth
Completed NCT02225353 - Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery Phase 2
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Completed NCT03144141 - Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery N/A
Completed NCT05210985 - Examination of the Relationship Between Home Affordances With Development
Completed NCT04021654 - What is the Future of Vulnerable New-borns